Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
about
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapyVariability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy.What does PD-L1 positive or negative mean?Prognostic value of PDL1 expression in pancreatic cancerProgrammed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.Quality Matters: 2016 Annual Conference of the National Infrastructures for Biobanking.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.Immune checkpoint inhibitors in lung cancer: an update.Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer.Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.Immunogenomics: using genomics to personalize cancer immunotherapy.PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.Advancing Immunotherapy in Metastatic Breast Cancer.PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1(+) and CD8(+) tumor-infiltrating T cells and outcome.Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.Her2 Challenge Contest: A Detailed Assessment of Automated Her2 Scoring Algorithms in Whole Slide Images of Breast Cancer Tissues.Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platformsPD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer.Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what's next?Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them.Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine.Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response.Current markers and their value in the era of immuno-oncology.PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?Atezolizumab in advanced non-small cell lung cancer.Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer.PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.
P2860
Q26741101-C3189BC8-2FDA-4F65-A7DF-609DCE83FA23Q33881490-9AE4C9C3-01F9-44CD-91EC-EC137E1C8F6BQ36939402-D4F38078-6317-43C8-840C-41153D144354Q37308194-01482659-D48E-4A1C-A57E-E38E8E9921C2Q37500381-33893005-8A68-40E1-903E-954604F9D7D5Q37687595-D660813B-9585-4437-BE03-6D7F917DDD31Q37691082-62D07733-BBA1-4C05-ABAC-2AC8E89F394EQ37702705-27CA4F5D-54D5-43EB-B081-6182AAF18465Q38372019-5DF2917B-19DB-4D1E-9897-72D5D67F76A3Q38374809-5C43278E-2723-4732-8CDF-3EB9D4C7D60CQ38401891-CF222987-C4B4-4417-ABC6-01F361C53236Q38629357-81FE32FA-A67F-4820-A351-7704BDE88447Q38645803-3F88E776-7A78-4EE9-AEC0-B6B225660274Q38673895-0B7922AD-F37F-4471-8193-99DE0D1E20BFQ38686642-5F54D469-7339-4C55-8509-9380795D9CD7Q38687867-AAFD3317-C3EE-46FF-9A08-98CA4A373AE4Q38742013-E2B04714-EB0D-4E13-9548-AB2F122826EEQ38772744-F7B61737-BB56-4212-82B1-B849A91FC963Q39036924-8489CAF8-C074-481C-8EE3-2B456F895E0DQ39324161-3F08D91E-73E3-4835-9310-445B16B41044Q39452745-DB0BBE72-2D31-41BD-A5FA-09A129BEA837Q40169855-CB8899EE-E658-439E-AAE9-3BD71D706D46Q40357824-AFE62827-B053-4264-B287-C7771CCF89F9Q40492032-2238F117-414B-4B4A-8152-8B750F7E7FA4Q41348743-41F661DA-F38C-470B-9FE1-23D54511D56BQ41550899-2B67BD82-21BB-47E7-98C5-ACF0BBDFBF81Q41709427-28E78637-B82C-4FA1-9304-72D897D692DDQ42340575-78B90244-F61D-482A-8E73-DE85918DA52CQ47105905-BDE2C649-F578-4F87-A594-F3C96B7DD04AQ47153925-A936E6C2-3001-4A81-A85F-32B471175316Q47161308-35A163F4-D658-4D41-9EFF-D5DFE98BEFFFQ47629539-DC2F4058-C81D-4D7C-B15A-F0B7E680AB7EQ47660305-C2FEB840-60CB-452F-81E9-C4C6EDC75C7FQ47721195-31CD275E-B610-4004-B648-E6508448B950Q48128973-133C091E-9E70-46BB-85C9-FCD2E79F0065Q48168816-EC634ED0-E1EC-4A73-BABA-F0611A228EDDQ48620065-7799A503-061B-42D2-B221-C31E18884BCFQ49259266-C3072BE4-3353-470D-952F-B6FB21C23CF0Q49417517-8C99419E-CA94-4768-9596-5B1F9487C661Q49494082-97221CAD-B664-4E49-BAFE-85530D3EC600
P2860
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Assessment of the PD-L1 status ...... egies in lung cancer patients.
@en
type
label
Assessment of the PD-L1 status ...... egies in lung cancer patients.
@en
prefLabel
Assessment of the PD-L1 status ...... egies in lung cancer patients.
@en
P2093
P2860
P1433
P1476
Assessment of the PD-L1 status ...... egies in lung cancer patients.
@en
P2093
Marius Ilie
Paul Hofman
Véronique Hofman
P2860
P2888
P304
P356
10.1007/S00428-016-1910-4
P577
2016-02-25T00:00:00Z